5-Bromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-2H-indol-2-one | 204003-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Bromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-2H-indol-2-one
• 英文别名: 5-bromo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indol-2-one
• CAS: 204003-89-4
• 化学式: C₁₇H₁₅BrN₂O
• 分子量: 343.2
• InChiKey: RFHPWPWVGFSLOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Deng Huayun

  公开号：US20120295965A1

  公开（公告）日：2012-11-22

  Disclosed are compositions and methods related to identification of modulators of EGFR and VEGFR.

  本发明涉及识别EGFR和VEGFR的调节剂的组合物和方法。
• TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS
  申请人：Wilhelm Scott

  公开号：US20100173954A1

  公开（公告）日：2010-07-08

  The present invention provides compositions and methods for treating cancer with DAST, 44-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide of the formula I, including all polymorphs, hydrates, pharmaceutically acceptable salts, metabolites, prodrugs, solvates or combinations thereof. Any cancer can be treated, including cancers that have acquired resistance to another therapeutic agent, such as kinase inhibitors. DAST can also be used to treat cancers which have become refractory to other chemotherapeutic agents

  本发明提供了使用DAST（44-[3-(4-氯-3-三氟甲基苯基)-尿素]-3-氟苯氧基}-吡啶-2-羧酸甲酰胺，I式），包括所有多晶形态、水合物、药学上可接受的盐、代谢物、前药、溶剂化合物或其组合物，治疗癌症的组合物和方法。可以治疗任何癌症，包括已经对其他治疗药物（如激酶抑制剂）产生耐药性的癌症。DAST还可用于治疗已经对其他化疗药物产生耐药性的癌症。
• Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
  申请人：Varner A. Judith

  公开号：US20060241067A1

  公开（公告）日：2006-10-26

  The invention relates to methods for detecting and inhibiting angiogenesis, cell migration, cell adhesion, and/or cell survival in endothelial and non-endothelial cells as well as in normal and tumor cells. The invention further relates to methods for screening test compounds for their ability to inhibit angiogenesis, cell migration, cell adhesion, and/or cell survival.

  本发明涉及检测和抑制内皮细胞和非内皮细胞以及正常细胞和肿瘤细胞的血管生成、细胞迁移、细胞粘附和/或细胞存活的方法。本发明还涉及筛选检测化合物抑制血管生成、细胞迁移、细胞粘附和/或细胞存活能力的方法。
• PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS
  申请人：SHIMOHATA Takayoshi

  公开号：US20120189631A1

  公开（公告）日：2012-07-26

  Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.
• US8652476B2
  申请人：——

  公开号：US8652476B2

  公开（公告）日：2014-02-18